key: cord-1038161-l096bg0w
authors: Chakraborty, Chiranjib; Sharma, Ashish Ranjan; Bhattacharya, Manojit; Agoramoorthy, Govindasamy; Lee, Sang-Soo
title: Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis
date: 2021-06-04
journal: Vaccines (Basel)
DOI: 10.3390/vaccines9060600
sha: f17b78e9649157d8515145087b9f379ef4683637
doc_id: 1038161
cord_uid: l096bg0w

COVID-19 vaccination has started throughout the globe. The vaccination program has also begun in most Asian countries. This paper analyzed the Asian-origin COVID-19 vaccines and vaccination program status in Asia till March 2021 under three sections. In the first section, we mapped the approved vaccines that originated from Asia, their technological platforms, collaborations during vaccine development, and regulatory approval from other countries. We found that a total of eight Asian COVID-19 vaccines originated and got approval from three countries: China, India, and Russia. In the second section, we critically evaluated the recent progress of COVID-19 vaccination programs. We analyzed the overall vaccination status across the Asian region. We also calculated the cumulative COVID-19 vaccine doses administered in different Asian countries, vaccine rolling in 7-day average in various Asian countries, and COVID-19 vaccine per day doses administrated in several Asian countries. We found that China and India vaccinated the maximum number of people. Finally, we evaluated the factors affecting the COVID-19 vaccination program in Asia, such as vaccine hesitancy, basic reproduction numbers (R0) and vaccination campaigns, and the cost of the vaccines. Our analysis will assist the implementation of the COVID-19 vaccination program successfully in Asia.

COVID-19 has created a public health emergency and presently is a global concern. This disease has caused more than 127 million infections and over 2.78 million deaths worldwide as of early 2020 [1] . The disease started in China and ended up across the world. There was a rapid rise in the infection rate during the first 3-4 months of 2020, reaching up to 80%. Nevertheless, the infection rate fell to 65% after implementing global travel restrictions [2] . COVID-19 also spread to different parts of Asia, and the number of infections was very high in Turkey, India, Indonesia, and Iran [3] [4] [5] [6] . The middle to low-income countries in Asia and the Asia-Pacific regions were the worst affected [6] . However, some success stories in controlling the spread of the disease are from small Asian countries such as Taiwan, Vietnam, and South Korea [7] . One of the best examples of the COVID-19 control model is from Taiwan, where only 600 cases and seven deaths were reported in 2020 among a total population of 24 million [7] [8] [9] [10] [11] . Other than Asia, a high number of infected patients were recorded in the USA and different countries in Europe [12, 13] . Several countries have commenced public health measures to reduce the

We collected the COVID-19 vaccine development and vaccination progress data in Asia from WHO [34] . We also searched the databases such as PubMed [35, 36] , Web of Science [37] , and Google Scholar [38] with different keywords. One example of search terms is "COVID-19 vaccines", "vaccine hesitancy," "COVID-19 vaccination," etc. As a result, we found several relevant information and studies.

We collected data from different other sources such as our world in data (our world in data for [39] , Vaccine Tracker (Coronavirus vaccine tracker) [40] , Statista (The COVID-19 vaccination Race in Asia) [41] , and COVID-NMA [42] . Furthermore, for clinical trial information of the Asian-origin-approved vaccines, we retrieved the data from ClinicalTrials.gov [43] . We also retrieved several data from the Biorender COVID-19 vaccine and therapeutic drugs tracker [44] .

We mapped different approved vaccines originating from Asia, their technological platforms, collaborations during vaccine development, and regulatory approval from other countries of Asian-origin vaccines.

At the same time, both the single and double doses of vaccination were analyzed in Asian countries. We analyzed the demographic coverage of the COVID-19 vaccination in Asia. The cumulative COVID-19 vaccine doses administered in different Asian countries, the vaccine rolling 7-day average across countries, and the vaccine per day doses administrated in multiple Asian countries were calculated. Different essential statistical tools were used for this analysis. For understanding the overall methodology of this study, a flowchart is presented in Figure 1 . 

We found a total of eight approved vaccines that originated from Asia till the end of March 2020 and were approved in at least one country. It includes Ad5-nCoV, BBIBP-CorV (Sinopharm), Sputnik V (Gamaleya), ZF2001 (RBD-Dimer), CoronaVac, EpiVacCorona, BBV152 (Covaxin), and CoviVac. A list for the developer of vaccines, country of origin, the dose details, efficacy, stability, temperature ( • C), and clinical trials number is presented in Table 1 and Figure 2 . We listed the technological platform of all the Asian-origin vaccines: conventional inactivated vaccines, viral vector vaccines, modified adenovirus vector-vaccine, and protein subunit vaccines. Four conventional inactivated vaccines that were noted are CoronaVac, BBV152 (Covaxin), BBIBP-CorV (Sinopharm), and CoviVac. Only one viral vector vaccine was observed (Sputnik V (Gamaleya)). Simultaneously, one modified adenovirus vector vaccine (Ad5-nCoV) and two protein subunit vaccines (EpiVacCorona and ZF2001(RBD-Dimer)) were observed (Table 1) . 

It is essential to understand the efficacy of the approved vaccines (originated from Asia). The approved vaccines have shown efficacy in clinical trials, and it is essential as it protects both the person and a country's population [53, 54] . In general, it was observed that most of the approved COVID-19 vaccines had efficacy in the range of 70-95% (Table 1) . We noted the efficacy of some of the important vaccines, which is as follows: Sputnik V with 91.6% [55] , BBIBP-CorV with 79.3% [56] ,Covaxin with 81% [57] .

Immediately after the preclinical stage, most COVID-19 vaccines started their clinical trials (phase-I, -II, and -III) to understand the safety and efficacy. We performed a survey (September-November 2020) and found that during this period, more than 55 vaccine candidates entered the list of clinical trials (source is from ClinicalTrials.gov). As of September-December 2020, we observed 27 vaccine candidates entering the phase-I clinical trials, 23 vaccine candidates entering the phase-II clinical trials, and 5 vaccines entering the phase-III clinical trials, respectively [22] . These trials were registered in the COVID-19 NMA database. We observed a total of 346 clinical trials (throughout the world) as of 21 May 2021. Among them, 246 were randomized, and 100 were nonrandomized clinical studies of COVID-19 vaccines. To this date, 169 clinical trials have recruited patients for the studies. The registration of the clinical trials was analyzed and mapped from the same database and is shown in Figure 3a . Of these, 27 clinical studies have published their data while two were terminated, one was suspended, and one was withdrawn. Different collaborations were made during the development of the vaccines. The significant associations during the development of the Asian-origin vaccines are shown in Table 2 . In addition, networking information was collected to understand the collaborations between the collaborating partners. The networking for the partnerships throughout the Asian countries is shown in Table 3 . 

The vaccines approved in various countries in Asia are shown in Figure 5a . All the eight approved vaccines and their approval country number are shown in Figure 5b . Due to the pandemic situation, most vaccines received emergency approval from regulatory authorities in Asia to fight the infection. 

We evaluated the demographic coverage in some Asian countries using the COVID-19 vaccination. The evaluation was regarding the population receiving at least one dose and those who were completely vaccinated. The vaccination report till 24 May 2021 was considered. In total, 11.1% of the total population (152.3 million) received at least one dose in India, and 3.1% of the population is wholly vaccinated (Figure 6a ). In China, 527.2 million vaccine doses were given to the people (Figure 6b) , and it aims to vaccinate 40% of its total population by the end of July 2021. In Japan, 5.2% of the population has received at least one dose, and 2.3% of the population is completely vaccinated ( Figure  6c) . In Malaysia, a total of 1.6 million vaccine doses were given to the people (Figure 6d ). In South Korea, 7.5% of the population has received at least one dose, and 3.6% is wholly vaccinated (Figure 6e ). In Singapore, 34.5% of the people have received at least one dose, and 25.3% are entirely vaccinated (Figure 6f ). In Bangladesh, 5.8 million vaccine doses were given to the people (Figure 6g ). In Hong Kong, 16.9% of the population has received at least one dose, and 12.1% are wholly vaccinated (Figure 6h ). In Russia, 10.8% of the people have received at least one dose, and 7.8% are completely vaccinated (Figure 6i) .

We recorded the COVID-19 vaccine administration in some countries (per 100 people in a country's total population) in Asia ( Figure 7a ) and found that China and India have vaccinated over 20 million doses (Figure 7b ) (last 14 days, the vaccination data from China is not correctly available). We also found that more than eight countries have administrated above 5 million vaccine doses within 14 days to people (Figure 7c ).

We calculated the cumulative COVID-19 vaccine dose administration in different Asian countries. In this case, we determined the cumulative COVID-19 vaccine in various Asian countries and represented it through a linear graph (Figure 8a ). We also calculated the cumulative COVID-19 vaccine in different Asian countries using log graph mode (Figure 8b ). Finally, we also represented the cumulative COVID-19 vaccine in various Asian countries using an Asian map and marked it through color variation (Figure 8c ).

We calculated the COVID-19 vaccine rolling 7-day average per 100 people in various Asian countries and represented it through a linear graph (Figure 9a ). The COVID-19 vaccine rolling 7-day average per 100 people in different Asian countries is represented using the log graph mode (Figure 9b ). In addition, we also represented the COVID-19 vaccine rolling 7-day average per 100 people in various Asian countries using an Asian map and marked it through color variation (Figure 9c ). We recorded the COVID-19 vaccine administration in some countries (per 100 people in a country's total population) in Asia (Figure 7a ) and found that China and India have vaccinated over 20 million doses (Figure 7b ) (last 14 days, the vaccination data from China is not correctly available). We also found that more than eight countries have administrated above 5 million vaccine doses within 14 days to people (Figure 7c ). 

We also calculated the COVID-19 vaccine per day dose administration in multiple Asian countries and represented it through a linear graph (Figure 10a) . Again, in this case, COVID-19 vaccine per day doses administrated in various Asian countries were described using the log graph mode (Figure 10b) . Furthermore, we also represented COVID-19 vaccine per day doses administration in multiple Asian countries using an Asian map and marked it through color variation (Figure 10c ). 

Vaccine hesitancy is one of the significant factors that hinder the vaccination drive. It is a global problem for vaccination [58] . Several models have been developed to understand vaccine hesitancy and have been divided into four main categories: The first category is the "vaccine acceptor group" or "vaccine acceptance," who agreed to take the vaccine. The second category is the "vaccine-hesitant group" or "vaccine-hesitancy," who may accept vaccination but with considerable concerns about the vaccination. The third category is the "late vaccinators group," who knowingly or purposefully delay the vaccinating process. The last category is the "rejector group," which rejects the vaccines [59] . For COVID-19 vaccination, several scientists have reported vaccine hesitancy as a significant problem [60] . Several researchers have tried to understand the COVID-19 vaccine acceptance rates [61] [62] [63] [64] . Lazarus et al. have performed a global survey about the vaccine acceptance rates that varied from country to country. They have demonstrated a range of vaccine acceptance rates from approximately 90% to 55% [65] . We noted vaccine hesitancy in Asian countries such as China, Kuwait, Malaysia, Indonesia, Russian, Hong Kong, Singapore, and India (Table 4 ). From the reviewed data from the published literature, we observed the highest vaccine acceptance rate in Malaysia (94.3%) and the lowest vaccine acceptance rate in Kuwait (23.6%) (Figure 11 ). The lowest vaccine acceptance rate was noted due to a lack of awareness of the COVID-19 vaccine and awareness or worry about getting sick due to vaccination. On the other hand, the highest vaccine acceptance rate was observed due to well-organized campaigns and awareness for COVID-19 vaccination. However, most of the surveys were performed using a random sample of the population from every country. Therefore, more COVID-19 vaccination campaigns are required for the lowest vaccine acceptance countries. 

Basic reproduction number (R0) is one of the critical factors for COVID-19 vaccination. The R0 metric is used to understand the transmissibility or contagiousness of infective agents. It is an epidemiologic metric [70] . Alimohamadi et al. calculated the mean R0 for COVID-19 through meta-analysis and systematic review from different reported articles.

The mean value of R0 was reported as 3.38 ± 1.40. In this analysis, the range of the R0 was noted as 1.90-6.49 [71] . It was pointed out that the pattern of R0 of COVID-19 during the COVID-19 pandemic period and the pattern of R0 influenza during influenza is more or less similar in respect to clinical severity and clinical characteristics [72] . Some Asian countries, such as Taiwan, tried to develop vaccination plans based on their previous preparedness strategies during the influenza pandemic [9] . Farrington has developed a model for R0 and the vaccine efficacy. He has shown a correlation between R0 and the projected effectiveness of a vaccination program (PE), which may help evaluate a vaccination program's effectiveness. The correlation is PE = 1 − (RV/R0), where PE = projected effectiveness of a vaccination program; RV= the projected reproduction number. This study observed Re(t), an effective reproduction number at time t. The time to time analysis of Re(t) is necessary over time, which is a significant feature of evaluating the vaccination program surveillance [61] . This study plotted the total no of infections and the vaccination progress (in a single dose) in some Asian countries ( Figure 12 ). 

The vaccine cost is an essential factor for the vaccination program, especially in low-and middle-income countries in Asia. The World Bank report in 2018 showed that 783 million people live in extreme poverty, and 42% of them are located in Asia. We tried to analyze the cost of Asian-origin vaccines ( Figure 13 ) and found that the Indian vaccine production company, the Serum Institute of India, produces the lowest-cost vaccine [73] . The Serum Institute of India has agreed with AstraZeneca to make the Covishield vaccine at a meager cost (USD 3 per dose), accessible by the developing countries across the world [74] . Presently, the Indian vaccines are distributed free from the government hospital for low-income people and USD 7 from private hospitals. 

We found that eight COVID-19 vaccines have been approved and originated from Asia, mainly from China, India, and Russia. Four of them are developed by China, one by India, and three by Russia. Furthermore, we observed that these vaccines belong to the four vaccine platforms (conventional inactivated vaccines, viral vector vaccines, modified adenovirus vector-vaccine, and protein subunit vaccines).

Asia is a focal point to conduct clinical trials due to its low cost. The clinical trial in Asia is comparatively 25-40% lower than USA [78, 79] . From the vaccine clinical trial point of view, we found the highest number of vaccine clinical trials is going on in China [22] . The second highest number of vaccine clinical trials are going in India [15] , and the lowest number of clinical trials are going in Malaysia [1] .

Most of the Asian countries have started their COVID-19 vaccination programs. Furthermore, we analyzed the COVID-19 vaccination program. Our evaluation showed that Singapore is the first country to administrate the COVID-19 vaccine per 100 populations among Asian countries (58.24%) (Figure 7a ) (41) . In addition, we found two Asian countries with 20 million vaccine doses (China and India) (Figure 7b ). However, the last 14 days vaccination data from China is not adequately available. Simultaneously, other countries (more than eight) have administrated 5 million vaccine doses to their population in the last 14 days (Figure 7c) .

It was observed that Chinese vaccines are sold in several low and middle-income Asian countries. Sinopharm, a Chinese vaccine, has conducted a phase III clinical trial in UAE and reported the vaccine's efficacy to be 86%. This vaccine is being sent to different countries such as Pakistan [80] . Another Chinese vaccine, CoronaVac, will be sold to other countries such as developing countries like Indonesia and Turkey [80] . The critical Russian vaccine, Sputnik V, was developed by the Gamaleya Research Institute and is being circulated to low and middle-income countries like Vietnam, India, and Nepal [81] .

Under the foreign policy, India is delivering the vaccine to the South Asian neighbors. India has donated over 5 million doses of these vaccines to various low-income countries such as Bangladesh, Bhutan, Afghanistan, Maldives, Sri Lanka, and Nepal [75, 82] .

All the Asian countries have started their COVID-19 vaccination with immense initiative and full efforts in small to medium populated countries and low to medium-income countries. However, vaccination programs are suffering from several unavoidable factors that hamper their progress, such as the cost of the COVID-19 vaccines, vaccine hesitancy, and vaccine illiteracy. Wouters et al. discussed several challenges for the global access to COVID-19 vaccines. They have highlighted the significant difficulties such as price, affordability, acceptance of COVID-19 vaccines, logistical and administrative challenges, storage requirements, and production capacities [76] . Thus, in this domain, more vaccina-tion campaigns and low-cost COVID-19 vaccines must support low to medium-income Asian countries to build up public trust and confidence in COVID-19 vaccines.

Fortunately, several COVID-19 vaccines have been produced within a year, and the vaccination programs have started across several countries to stop the pandemic. However, at the same time, significant planning and good execution are required to vaccinate the entire population of each country to end the pandemic.

Nevertheless, several essential questions still need to be resolved by the researchers. One of them is to evaluate the durability of the protective immune responses of the COVID-19 approved vaccines. At the same time, several mutated variants have originated in recent times, which include B.1.351 lineage (South Africa), B.1.1.7 lineage (United Kingdom), and P.1 lineage (Brazil). Currently, these variants are circulating throughout Asia. Therefore, can the existing COVID-19 vaccines generate the protective immune responses for the newly mutated variants, or do we need to develop new vaccines? Therefore, for the betterment of the human race, we need to resolve these questions quickly.

However, our analysis will advance the understanding of the vaccination program taken by different Asian countries to improve future vaccination strategies. 

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)

COVID-19 Outbreak and Turkey. Turk. Thorac

The rise and impact of COVID-19 in India. Front

COVID-19 in Indonesia: Challenges and Multidisciplinary Perspectives for a Safe and Productive New Normal

COVID-19 in Iran: Forecasting Pandemic Using Deep Learning

The impact of the COVID-19 outbreak on Asia-Pacific health systems. In Health at a Glance: Asia/Pacific 2020: Measuring Progress Towards Universal Health Coverage

COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions

Proactive and blended approach for COVID-19 control in Taiwan

Taiwan's Model for Combating COVID-19: A Small Island with Big Data

Control of the COVID-19: A Successful Model of a Small Island

Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation

The COVID-19 pandemic in the US: A clinical update

Ranking the effectiveness of worldwide COVID-19 government interventions

COVID-19 vaccines: Where we stand and challenges ahead

India's cost-effective COVID-19 vaccine development initiatives

India will supply coronavirus vaccines to the world-Will its people benefit? Nat

Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust

China's coronavirus vaccines are leaping ahead-but face challenges as virus wanes

Evolution and variation of 2019-novel coronavirus

Development of epitopebased peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach

Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic

With record-setting speed, vaccinemakers take their first shots at the new coronavirus

The COVID-19 vaccine development landscape

Evolution of the COVID-19 vaccine development landscape

Responding to Covid-19-A once-in-a-century pandemic?

Controlling epidemics with transmissible vaccines

The contribution of vaccination to global health: Past, present and future

A brief history of vaccines & vaccination in India

Global yellow fever vaccination coverage from 1970 to 2016: An adjusted retrospective analysis

Early warning of vulnerable counties in a pandemic using socio-economic variables

Demographic characteristics of persons vaccinated during the first month of the COVID-19 vaccination program-United States

Key steps in our journey to a COVID-19 vaccine program

Available online: www

How do we share data in COVID-19 research? A systematic review of COVID-19 datasets in PubMed Central Articles

Two Weeks of "COVID-19

Bibliometric analysis of coronavirus disease (COVID-19) literature published in Web of Science 2019-2020

Using Google Scholar to track the scholarly output of research groups

Coronavirus Disease (COVID-19)-Statistics and Research

The COVID-19 Vaccination Race in Asia

Building an Evidence Ecosystem for the COVID-19 Pandemic

Trial reporting in ClinicalTrials.gov-The final rule

COVID-19 Vaccine & Therapeutics Tracker. Available online

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A ran-domised, double-blind, placebo-controlled, phase 2 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two ran-domised, double-blind, placebo-controlled, phase 1 and 2 trials

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Russia in the Global 'Vaccine Race'. OSW Commentary

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial

A review on how exactly covid-19 vaccination works

What does 95% COVID-19 vaccine efficacy really mean?

Sputnik V COVID-19 vaccine candidate appears safe and effective

Adjuvantation helps to optimise COVID-19 vaccine candidate

Announces Phase 3 Results of COVAXIN®: India's First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%. Available online: www

Vaccine hesitancy: An overview. Hum. Vaccines Immunother

Qualitative Analysis of Mothers' Decision-Making About Vaccines for Infants: The Importance of Trust

Covid-19: Vaccine hesitancy fell after vaccination programme started

COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates

Modification of a vaccine hesitancy scale for use in adult vaccinations in the United States and China

Acceptability of a COVID-19 Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia

Vaccine Hesitancy and Demand for Immunization in Eastern Europe and Central Asia: Implications for the Region and Beyond

El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine

The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum. Vaccines Immunother

Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. Front

High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries

Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey

Complexity of the Basic Reproduction Number (R0)

Estimate of the Basic Reproduction Number for COVID-19: A Systematic Review and Meta-analysis

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

On vaccine efficacy and reproduction numbers

COVID-19 vaccine: Challenges in developing countries and India's initiatives

China Sinopharm Chief Rules Out High Price for Coronavirus Vaccine

Covid-19: What do we know about Sputnik V and other Russian vaccines? BMJ 2021, 372, n743

Refrigeration of COVID-19 Vaccines: Ideal Storage Characteristics, Energy Efficiency and Environmental Impacts of Various Vaccine Options

Clinical trials in Asia: A World Health Organization database study

Evolution of the clinical trial landscape in Asia Pacific

COVID-19 vaccines for low-and middle-income countries

India's domestic and foreign policy responses to COVID-19

Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment

Institutional Review Board Statement: Not applicable.

Data Availability Statement: Not applicable.

The authors have no conflict of interest to declare.